You just read:

Daiichi Sankyo's Pexidartinib Demonstrated Further Improvement with Continued Treatment of Tenosynovial Giant Cell Tumor Patients in New Long-Term Analysis Presented at 2019 ASCO Annual Meeting

News provided by

Daiichi Sankyo Company, Limited

Jun 01, 2019, 08:00 ET